Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 3

3(42.9%)

Phase 2

1(14.3%)

7Total

Phase 1(3)

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02842541Phase 1Withdrawn

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

Role: lead

NCT02492321Phase 3Completed

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

Role: lead

NCT01998802Phase 3Completed

Phase 3 Study of EBI-005 in Dry Eye Disease

Role: lead

NCT02405039Phase 3Unknown

Study of EBI-005 in Dry Eye Disease (DED)

Role: lead

NCT02082899Phase 2Completed

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Role: lead

NCT01745887Phase 1Completed

A Multi-Center Study Subjects With Dry Eye Syndrome

Role: lead

NCT01748578Phase 1Completed

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects

Role: lead

All 7 trials loaded